Efficacy and Safety of Paromomycin for Visceral Leishmaniasis: A Systematic Review | Zendy

Pashupati Pokharel | Zendy; Rakesh Ghimire | Zendy; Pratik Lamichhane | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Efficacy and Safety of Paromomycin for Visceral Leishmaniasis: A Systematic Review

Author(s) -

Pashupati Pokharel,

Rakesh Ghimire,

Pratik Lamichhane

Publication year - 2021

Publication title -

journal of tropical medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.747

H-Index - 30

eISSN - 1687-9694

pISSN - 1687-9686

DOI - 10.1155/2021/8629039

Subject(s) - paromomycin , visceral leishmaniasis , leishmaniasis , medicine , drug resistance , aminoglycoside , intensive care medicine , immunology , antibiotics , biology , microbiology and biotechnology

Visceral leishmaniasis, also known as kala-azar is one of the most commonly neglected tropical diseases affecting a large number of rural and resource-limited people in South Asia, Africa, and South America. Paromomycin, an aminoglycoside drug, is frequently used for the treatment of visceral leishmaniasis. Despite limited therapies for visceral leishmaniasis and emerging drug resistance, a proper review on the action of paromomycin for kala-azar is lacking. This systematic review aims to look for the efficacy and safety aspects of paromomycin for the treatment of visceral leishmaniasis.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research